Align probiotic goes national
This article was originally published in The Tan Sheet
Executive SummaryProcter & Gamble's patented probiotic dietary supplement Align reaches store shelves in its nationwide launch, the firm announces May 12. The trademarked bacterial strain in the product, Bifantis, is "clinically proven to help promote the balance of healthy bacteria in the digestive system and to help build and maintain an ongoing natural defense against the five signs of episodic digestive imbalance - constipation, diarrhea, urgency, gas and bloating," the firm says. A 28-count bottle of the once-daily product retails for approximately $30. P&G licenses Bifantis from Irish specialty biotech firm Alimentary Health. P&G holds the trademark and has patent protection until 2020. Marketing initiatives to support the launch include partnering with "celebrity nutritionist" Ashley Koff in an essay contest about consumers' digestive health at 1www.MyDigestiveMakeover.com (2"The Tan Sheet" April 20, 2009, p. 17)
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.